AMSSM scientific statement concerning viscosupplementation injections for knee osteoarthritis: importance for individual patient outcomes.
British journal of sports medicine
Female, Humans, Hyaluronic Acid, Injections, Intra-Articular, Male, Middle Aged, Osteoarthritis, Knee, Randomized Controlled Trials as Topic, Viscosupplementation, Viscosupplements
Osteoarthritis (OA) is a disabling disease that produces severe morbidity reducing physical activity. Our position statement on treatment of knee OA with viscosupplementation injection (hyaluronic acid, HA) versus steroid (intra-articular corticosteroids, IAS) and placebo (intra-articular placebo, IAP) is based on the evaluation of treatment effect by examining the number of participants within a treatment arm who met the Outcome Measures in Rheumatoid Arthritis Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) criteria, which is different and more relevant than methods used in other reviews which examined if the average change across the treatment groups were clinically different. We performed a systematic literature search for all relevant articles from 1960 to August 2014 in the MEDLINE, EMBASE and Cochrane CENTRAL. We performed a network meta-analysis (NMA) of the relevant literature to determine if there is a benefit from HA as compared with IAS and IAP. 11 papers met the inclusion criteria from the search strategy. On NMA, those participants receiving HA were 15% and 11% more likely to respond to treatment by OMERACT-OARSI criteria than those receiving IAS or IAP, respectively (p
Trojian, Thomas H; Concoff, Andrew L; Joy, Susan M; Hatzenbuehler, John R; Saulsberry, Whitney J; and Coleman, Craig I, "AMSSM scientific statement concerning viscosupplementation injections for knee osteoarthritis: importance for individual patient outcomes." (2016). Maine Medical Center. 815.